Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-060314
Filing Date
2025-04-29
Accepted
2025-04-29 17:05:17
Documents
98
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bbio-20250331.htm   iXBRL 10-Q 4009326
2 EX-10.1 bbio-ex10_1.htm EX-10.1 57489
3 EX-31.1 bbio-ex31_1.htm EX-31.1 29749
4 EX-31.2 bbio-ex31_2.htm EX-31.2 29845
5 EX-31.3 bbio-ex31_3.htm EX-31.3 28357
6 EX-32.1 bbio-ex32_1.htm EX-32.1 13518
7 EX-32.2 bbio-ex32_2.htm EX-32.2 13776
8 EX-32.3 bbio-ex32_3.htm EX-32.3 13198
  Complete submission text file 0000950170-25-060314.txt   19307191

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT bbio-20250331.xsd EX-101.SCH 3057311
101 EXTRACTED XBRL INSTANCE DOCUMENT bbio-20250331_htm.xml XML 3896198
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38959 | Film No.: 25889072
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)